86 related articles for article (PubMed ID: 26303977)
1. Time Savings with Once-Monthly C.E.R.A.: A Time and Motion Study Conducted in 13 Haemodialysis Centres in Italy.
De Cock E; Kritikou P; Ravera S; Filippini A
Blood Purif; 2015; 40(2):173-9. PubMed ID: 26303977
[TBL] [Abstract][Full Text] [Related]
2. Time savings associated with C.E.R.A. once monthly: a time-and-motion study in hemodialysis centers in five European countries.
De Cock E; Dellanna F; Khellaf K; Klatko W; Maduell F; Raluy-Callado M; Villa G
J Med Econ; 2013; 16(5):648-56. PubMed ID: 23402559
[TBL] [Abstract][Full Text] [Related]
3. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource utilization for anemia management: current practice with erythropoiesis-stimulating agents and the impact of converting to once-monthly C.E.R.A.
Saueressig U; Kwan JT; De Cock E; Sapède C
Blood Purif; 2008; 26(6):537-46. PubMed ID: 18997465
[TBL] [Abstract][Full Text] [Related]
5. Time savings of weekly versus three-times-per-week administration of erythropoiesis stimulating agents in United States dialysis patients.
Stephens JM; Emerson LC; Spry LA; Caloyeras JP; Anderson ER; Reitan JF; Ashfaq A
Curr Med Res Opin; 2016; 32(2):313-20. PubMed ID: 26583202
[TBL] [Abstract][Full Text] [Related]
6. Administration of erythropoiesis-stimulating agents in patients undergoing haemodialysis: A time and motion study.
Johnson DW; Cleland B; Eris J; Rafferty T; Sud K; Chow JS
J Ren Care; 2017 Dec; 43(4):219-225. PubMed ID: 28901048
[TBL] [Abstract][Full Text] [Related]
7. Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres.
Perrinet M; Décaudin B; Champs BB; Heran I; Urbina MA; Lemaitre V; Azar R; Odou P
J Clin Pharm Ther; 2010 Aug; 35(4):395-400. PubMed ID: 20831542
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
9. Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study.
Dellanna F; Winkler RE; Bozkurt F; Schettler V; Graf S; Bockreiss N; Fliser D;
Int J Clin Pract; 2011 Jan; 65(1):64-72. PubMed ID: 21091595
[TBL] [Abstract][Full Text] [Related]
10. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Yong K; Kairaitis L
Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
[TBL] [Abstract][Full Text] [Related]
11. Factors related to the absence of anemia in hemodialysis patients.
Verdalles U; Abad S; Vega A; Ruiz Caro C; Ampuero J; Jofre R; Lopez-Gomez JM
Blood Purif; 2011; 32(1):69-74. PubMed ID: 21346339
[TBL] [Abstract][Full Text] [Related]
12. [Current issues in erythropoietin therapy of renal anemia].
Zakar G
Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia.
Chanu P; Gieschke R; Charoin JE; Pannier A; Reigner B
J Clin Pharmacol; 2010 May; 50(5):507-20. PubMed ID: 20179322
[TBL] [Abstract][Full Text] [Related]
14. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
15. Staff time and motion assessment for administration of erythropoiesis-stimulating agents: a two-phase pilot study in clinical oncology practices.
Reitan JF; van Breda A; Corey-Lisle PK; Shreay S; Cong Z; Legg J
Clin Drug Investig; 2013 May; 33(5):383-9. PubMed ID: 23553358
[TBL] [Abstract][Full Text] [Related]
16. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study.
de Francisco AL; Sulowicz W; Klinger M; Niemczyk S; Vargemezis V; Metivier F; Dougherty FC; Oguey D;
Int J Clin Pract; 2006 Dec; 60(12):1687-96. PubMed ID: 17109676
[TBL] [Abstract][Full Text] [Related]
17. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia.
Majoni SW; Ellis JA; Hall H; Abeyaratne A; Lawton PD
Hemodial Int; 2014 Oct; 18(4):740-50. PubMed ID: 24766376
[TBL] [Abstract][Full Text] [Related]
18. Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: the AnemiaTrans Study.
Sánchez-Fructuoso AI; Ruiz JC; Torregrosa JV; González E; Gómez E; Gallego RJ; Troya MI; Jimenez C; Llamas F; Romero R; Bernis C; Crespo JF; Guirado L;
Adv Ther; 2012 Nov; 29(11):979-91. PubMed ID: 23160946
[TBL] [Abstract][Full Text] [Related]
19. Comparison between Long- and Short-Acting Erythropoiesis-Stimulating Agents in the Period Required for Haemoglobin Stabilisation in Treatment of Anaemia in Patients with Chronic Kidney Disease.
Hayashi T; Nagamatsu T; Matsushita A; Mizuno T; Nishibe S; Noguchi A; Kato R; Toda T; Tanaka J; Takahashi H; Hayashi H; Yuzawa Y; Yamada S
Biol Pharm Bull; 2015; 38(5):740-5. PubMed ID: 25740003
[TBL] [Abstract][Full Text] [Related]
20. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
